Description: Innoblative Designs is addressing unmet clinical needs for patients with breast cancer and other soft tissue diseases, received Breakthrough Device Designation from the FDA for the company's SIRA® RFA Electrosurgical Device.
designs (2998) surgery (1654) surgical (374) applicator (34) ablation (29) margins (16) excision (10) rf ablation (2) innoblative (1) coagulate (1)
09/04/19 - Innoblative Welcomes Kelly Londy as Chief Executive Officer Read More
Innoblative, a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue disease, received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company's SIRA™ RFA Electrosurgical Device (SIRA). The SIRA device is intended for use in breast cancer patients undergoing BCS, commonly referred to as lumpectomy. Innoblative's SIRA™ device has a unique spherical shape to the entire cavity that circumferentially delivers
Committed to innovative surgical solutions